Patents Assigned to Merck, Sharp & Dohms, Corp.
  • ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
    Publication number: 20220033496
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
    Type: Application
    Filed: June 3, 2021
    Publication date: February 3, 2022
    Applicants: Merck Sharp & Dohme Corp., Agenus Inc.
    Inventors: Milan BLANUSA, Barbara JOYCE-SHAIKH, Andrea Claudia SCHUSTER, Kornelia SCHULTZE, Luis A. ZUNIGA
  • Cyclic Di-Nucleotide Compounds as STING Agonists
    Publication number: 20220024964
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds (I).
    Type: Application
    Filed: December 2, 2019
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220025042
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • CELL-BASED BIOIDENTITY TEST FOR INSULIN
    Publication number: 20220026414
    Abstract: A functional cell-based assay for use as a bioidentity assay for insulin or insulin analogs is described. The assay may be used as a replacement of the rabbit blood sugar method disclosed in USP<121> Insulin Assays.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: Junming Yie
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220025043
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
    Patent number: 11230556
    Abstract: The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xiaolei Gao, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Debra L. Ondeyka
  • Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
    Patent number: 11230543
    Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
  • Progressively-trained scale-invariant and boundary-aware deep neural network for the automatic 3D segmentation of lung lesions
    Patent number: 11232572
    Abstract: A system and method are disclosed for segmenting a set of two-dimensional CT slices corresponding to a lesion. In an embodiment, for each of at least a subset of the set of CT slices, the system inputs the CT slice into a plurality of branches of a trained segmentation block. Each branch of the segmentation block includes a convolutional neural network (CNN) with filters at a different scale, and produces one or more levels of output. The system generates, for each CT slice in the subset, feature maps for each level of output. The system generates a segmentation of each CT slice in the subset based on the feature maps of each level of output. The system aggregates the segmentations of each slice in the subset to generate a three-dimensional segmentation of the lesion. The system transmits data representing the three-dimensional segmentation to a user interface for display.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Antong Chen, Gregory Goldmacher, Bo Zhou
  • CMV neutralizing antigen binding proteins
    Patent number: 11230591
    Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 25, 2022
    Assignees: Merck Sharp & Dohme Corp., The Board of Regents, The University of Texas System
    Inventors: Tong-Ming Fu, Aimin Tang, Dai Wang, Zhiqiang An, Ningyan Zhang, Sha Ha
  • Purine inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 11230547
    Abstract: The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth A. McGowan, Jason D. Katz, Matthew Christopher, Hua Zhou, David James Witter, Chaomin Li, John Lampe, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu
  • AUTOMATED BIOMANUFACTURING SYSTEMS, FACILITIES, AND PROCESSES
    Publication number: 20220017851
    Abstract: Disclosed are a process and an automated facility for manufacturing a purified protein of interest. The protein of interest can be a recombinant or naturally occurring protein and/or a therapeutic or other medically useful protein. For example, the disclosed process and automated facility are useful for manufacturing a purified protein drug substance.
    Type: Application
    Filed: August 8, 2021
    Publication date: January 20, 2022
    Applicants: Just-Evotec Biologics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Michael Wayne Vandiver, Eva Fan Gefroh, Rebecca Eileen McCoy, Robert James Piper, JR., Mark A. Brower, Nuno J. Dos Santos Pinto, William N. Napoli, Rachel Y. Straughn, Lisa A. Connell-Crowley, Megan J. McClure
  • PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220016031
    Abstract: A process for preparing and isolating pharmaceutical active ingredient particles having a particle size of between about 0.1 and 30 microns, wherein a slurry comprising the active ingredient and one or more pharmaceutically acceptable excipients is fed into a thin film evaporator under suitable conditions for less than 10 minutes sufficient to generate solid matrix particles comprising active ingredient and one or more excipients, wherein the particles have less than 5% residual solvent.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Luke R. Schenck, David J. Lamberto, Joseph L. Kukura, II, Francisco J. Guzman, Aaron Cote, Athanas Koynov
  • CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS
    Publication number: 20220017525
    Abstract: The present invention is directed to cyclobutyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Jason M. Cox, John S. Debenham, Zhuyan Guo, Zhong Lai, Dongfang Meng
  • PYRAZOLOPYRIMIDINE PDE9 INHIBITORS
    Publication number: 20220017526
    Abstract: The present invention is directed to amino and alkyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Jason M. Cox, John S. Debenham, Zhe Feng, Zhuyan Guo, Dongfang Meng
  • Antidiabetic bicyclic compounds
    Patent number: 11225471
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia Formula (I).
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: January 18, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Duane DeMong, Kevin D. Dykstra, Zhiyong Hu, Michael Miller
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220010011
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 13, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMA
    Publication number: 20220010016
    Abstract: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.
    Type: Application
    Filed: October 17, 2019
    Publication date: January 13, 2022
    Applicants: BioLineRx Ltd., Merck Sharp & Dohme Corp.
    Inventors: Abi VAINSTEIN-HARAS, Ella SORANI, Irit GLIKO-KABIR, Osnat BOHANA-KASHTAN, Amnon PELED
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220010010
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 13, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Fluorometric and colorimetric quantification techniques with autonomously and reversibly stalling catalytic signal amplification
    Patent number: 11220703
    Abstract: Provided herein are analytical methods utilizing a self-limiting catalytic reaction, and compositions and kits useful therefore. In one aspect the method is used to quantify Pd, and in another, the method is a horseradish peroxidase assay.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: January 11, 2022
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Merck Sharp & Dohme Corp.
    Inventors: Xiaodong Bu, Junyong Jo, Kazunori Koide, Matthew Patrick Tracey, Christopher J. Welch
  • Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
    Patent number: 11219680
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which polysaccharides obtained from bacterial capsules are conjugated to diphtheria toxin fragment B (DTFB) or a variant thereof. The immunogenic compositions may be multivalent pneumococcal polysaccharide conjugate compositions in which polysaccharides from one or more Steptococcus pneumoniae serotypes are conjugated to diphtheria toxin fragment B (DTFB) and, optionally, additional polysaccharides from one or more different Steptococcus pneumoniae serotypes are conjugated to one or more other carrier proteins.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 11, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John E. MacNair, Michael A. Winters, Thomas Svab, Sheng-Ching Wang, William J. Smith, Cecilia Giovarelli